Resource Summary Report

Generated by SPARC SAWG on Sep 6, 2026

FITC anti-mouse/human CD11b

RRID:AB_312789
Type: Antibody

Proper Citation

BioLegend Cat# 101206, RRID:AB_312789

Antibody Information

URL: http://antibodyregistry.org/AB_312789

Proper Citation: BioLegend Cat# 101206, RRID:AB_312789

Target Antigen: CD11b

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-mouse/human CD11b

Description: This monoclonal targets CD11b

Target Organism: cynomolgus, mouse, rhesus, human

Clone ID: Clone M1/70

Antibody ID: AB_312789

Vendor: BioLegend

Catalog Number: 101206

Alternative Catalog Numbers: 101205

Record Creation Time: 20231110T045028+0000

Record Last Update: 20260901T052332+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-mouse/human CD11b.

No alerts have been found for FITC anti-mouse/human CD11b.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 159 mentions in open access literature.

Listed below are recent publications. The full list is available at SPARC SAWG .

Niu Y, et al. (2026) Adoptive transfer of TregIL-33 cells ameliorates acute graft-versus-host disease by regulating the HPGD/PGE2 pathway. International immunopharmacology, 168(Pt 1), 115700.

Izawa K, et al. (2026) IgE-dependent anaphylaxis is regulated by sphingolipid binding to activating and inhibitory CD300 family members. Cell reports, 45(3), 117054.

Shang X, et al. (2026) Dual PD-1/IL-2R? targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC. Cell reports. Medicine, 7(3), 102633.

Jiang N, et al. (2026) Dual-targeted microspheres reshape the metabolic-immune microenvironment to reverse post-embolization dilemmas in hepatocellular carcinoma. Cell reports. Medicine, 7(5), 102748.

Liu L, et al. (2026) Ginsenoside compound K up-regulates ?-subunits of long-chain L-3-hydroxyacyl-CoA (HADHB) to promote fatty acid oxidation recovery and improve the balance of macrophage polarization in mice with ulcerative colitis. British journal of pharmacology, 183(13), 3633.

Ling H, et al. (2026) An inhalable microbe-oncolytic virus consortium for lung cancer treatment. Cell reports. Medicine, 7(5), 102771.

Liang Z, et al. (2026) Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling. Cancer cell, 44(6), 1235.

Zhou L, et al. (2026) p21-Positive Senescent Stromal Cells Promote Prostate Cancer Immune Suppression and Progression That Can Be Reversed by Senolytic Therapy. Cancer discovery, 16(3), 571.

Zhang SW, et al. (2026) Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment. Cell, 189(4), 1039.

Lei F, et al. (2026) Therapeutic Effect of Gemcitabine Combined With Angelica Polysaccharide on Triple Negative Breast Cancer in Mice. Integrative cancer therapies, 25, 15347354251414897.

Wang J, et al. (2026) The phosphatase DUSP2 constrains lymphoid remodeling and immunotherapy response in lung squamous carcinoma. Molecular therapy : the journal of the American Society of Gene Therapy, 34(7), 4279.

Kim EY, et al. (2026) Systemic immunometabolic profiling classifies cisplatin sensitivity states using interpretable machine learning. iScience, 29(3), 115037.

Pei Z, et al. (2026) STAT3 interference-driven nanomodulators reverse lipid metabolism-associated chemoresistance and potentiate metalloimmunotherapy in breast cancer. Cell reports. Medicine, 7(6), 102844.

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. Cell reports. Medicine, 102532.

Yan W, et al. (2026) Aurkb deficiency disrupts microglial development, homeostasis and hinders remyelination following cuprizone-induced demyelination. iScience, 29(2), 114718.

Wang H, et al. (2026) Targeting the macrophage mechanosensing regulator CKAP4 accelerates the inflammatory-to-proliferative transition in wound healing. Cell reports, 45(6), 117395.

Zhang Y, et al. (2026) Targeting EP2/EP4-driven expansion of suppressive VSIG4high macrophages overcomes immunotherapy resistance in colorectal cancer. Cell reports, 45(6), 117450.

Zhao L, et al. (2026) Apatinib enhances anti-PD-1 efficacy by inhibiting Exo70-mediated exosome secretion in pMMR/MSS colorectal cancer. NPJ precision oncology.

Thurimella K, et al. (2026) Identifying microbial protease allergens through protein language model-guided homology. Cell systems, 17(3), 101510.

Wang J, et al. (2026) VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma. Journal for immunotherapy of cancer, 14(5).